Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

This trial is testing whether adding toripalimab (an immunotherapy drug) to standard neoadjuvant chemotherapy before radiation improves outcomes for people with locoregionally advanced nasopharyngeal carcinoma — a cancer at the back of the nasal cavity that is most common in certain parts of Asia. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with locally advanced nasopharyngeal carcinoma (NPC), stage III–IVA/B - Your cancer is the non-keratinizing type (per WHO criteria) - You have normal bone marrow, thyroid, and organ function - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You are under 18 or over 65 - Your cancer has spread to distant organs - You have already started treatment for NPC - You have poor organ function or a significant autoimmune condition Talk to your doctor to see if this trial is right for you.